Joel E Tocker

USPTO Granted Patents = 12 (Patent Applications = 10)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.6

ph-index = 7

Forward Citations = 102(Granted Patents)

Location History:

Narberth, PA (US) (2014)
Issaquah, WA (US) (2010 - 2024)

Company Filing History:

Years Active: 2010-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858999 - IL-17 receptor A antigen binding proteins (2024-01-02),

2. 11180564 - IL-17 Receptor A antigen binding proteins (2021-11-23),

3. 10208122 - IL-17 receptor A antigen binding proteins (2019-02-19),

4. 9096673 - IL-17 receptor A antigen binding proteins (2015-08-04),

5. 9073999 - Anti-IL-17 receptor A neutralizing antibodies (2015-07-07),

6. 8790648 - Methods of treating psoriasis using IL-17 receptor A antibodies (2014-07-29),

7. 8545842 - Polynucleotides encoding IL-17 receptor A antigen binding proteins (2013-10-01),

8. 8435518 - Methods of using IL-17 receptor a antibodies (2013-05-07),

9. 7939070 - IL-17 receptor A antigen binding proteins (2011-05-10),

10. 7833527 - Methods of treating psoriasis using IL-17 Receptor A antibodies (2010-11-16),

11. 7786284 - Polynucleotides encoding IL-17 receptor A antigen binding proteins (2010-08-31),

12. 7767206 - Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto (2010-08-03),

Title: Innovator Joel E. Tocker: Pioneering Advances in IL-17 Receptor A Technology

Introduction

Joel E. Tocker, an accomplished inventor based in Issaquah, Washington, has made significant contributions to the field of biotechnology. With a robust portfolio of 12 patents, Tocker's work primarily revolves around the innovative realm of IL-17 receptor A antigen binding proteins, showcasing his commitment to advancing medical science.

Latest Patents

Among his most recent innovations are patents focused on IL-17 receptor A (IL-17RA) antigen binding proteins. These inventions encompass antibodies, polynucleotide sequences that encode these antigen binding proteins, and various methods for diagnosing and treating diseases related to IL-17RA activation by IL-17 ligands. Tocker's latest work highlights the identification of neutralizing determinants on IL-17RA and the development of antibodies that specifically bind to these determinants. This work also includes antibodies that demonstrate competitive binding with established IL-17RA neutralizing antibodies, offering potential breakthroughs in therapeutic treatments.

Career Highlights

Throughout his career, Tocker has affiliated with prestigious companies such as Amgen Inc. and Kirin-Amgen, Inc. His tenure at these organizations has significantly impacted the advancement of therapeutic solutions to complex medical issues.

Collaborations

Tocker has had the opportunity to collaborate with notable colleagues, including Jacques J. Peschon and James F. Smothers. These professional relationships have fostered an environment of shared knowledge and innovation, essential for groundbreaking developments in their field.

Conclusion

In summary, Joel E. Tocker’s extensive patent portfolio and collaborative efforts position him as a notable figure in the field of biotechnology. His contributions, particularly in the area of IL-17 receptor A antigen binding proteins, hold the promise of advancing diagnosis and treatment options for diseases linked to IL-17 receptor A activation. His innovative spirit continues to drive progress, benefiting both the scientific community and patients worldwide.

This text is generated by artificial intelligence and may not be accurate.